Q&A Automated, localized, fast: why a top apparel leader is getting behind unspun’s fabric tech By Milo Werner
Snapshot Kanvas Bio speeds the search for microbiome therapies through industrial-scale imaging of gut and host cells By Jason Pontin
Company Profile Flexible Power for an inflexible grid: Why DCVC backed Mainspring Energy By Milo Werner
Company Profile Built to break barriers: How Grove Biopharma is architecting its way around traditional drug limits By Dr. Emily Park, Dr. Kiersten Stead
Company Profile Elo’s breakthrough science offers scalable, domestic solutions to replacing sugar and artificial sweeteners By Dr. Justin Kern
News ShennonBio, a pioneer in precision cancer therapies, enters next phase of growth with a new CEO and fresh capital By James Hardiman
News DCVC co-leads Emerald AI’s $150 million Series A round to transform data centers into intelligent grid-responsive assets By Zachary Bogue, Kristen Rocca
Commentary Winning the quantum race: America’s blueprint for dominating the next tech revolution By Dr. Prineha Narang
Thoughts Professor Prineha Narang joins DCVC as we double down on our historical quantum tech leadership By Matthew Ocko, Zachary Bogue
Deep Tech Opportunities Report DCVC publishes the 2026 Deep Tech Opportunities report: “Back to Fundamentals in an Age of Exponential Change” By Matthew Ocko, Zachary Bogue
Deep Tech Opportunities Report Deep Tech Opportunity: Startup-built technologies are bringing us new ways to dominate in the air and in space
Deep Tech Opportunities Report Deep Tech Opportunity: There’s an exciting new way to put protein-like drugs inside cells
Deep Tech Opportunities Report Deep Tech Opportunity: It’s time to develop better drugs to treat anxiety